Previous 10 | Next 10 |
Wall Street Firms Are Bullish On These 5 Cheap Stocks Finding cheap stocks to buy doesn’t have to be complicated. Discovering new trends and opportunities early. Just look at the surging stocks this week like Virpax Pharma ( NASDAQ: VRPX ) and SGOCO Group, Ltd. ( ...
AcelRx Pharmaceuticals, Inc. (ACRX) Q2 2021 Results Conference Call August 16, 2021 4:30 PM ET Company Participants Vincent Angotti – Chief Executive Officer Raffi Asadorian – Chief Financial Officer Pamela P. Palmer – Chief Medical Officer Conference Call Participants Br...
AcelRx Pharmaceuticals Reports Second Quarter 2021 Financial Results $55.3 million of cash and short-term investments as of June 30, 2021 Q2 2021 DSUVIA sales of $0.4M, a 117% increase compared to Q1 2021 516 formulary approvals as of July 31, 2021 PR Newswire ...
New York, New York--(Newsfile Corp. - August 12, 2021) - Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating potential claims involving directors and officers regarding possible breaches of fiduciary duties related to whether insiders caused their companies ...
AcelRx to Host Second Quarter 2021 Financial Results Call and Webcast on August 16, 2021 PR Newswire HAYWARD, Calif. , Aug. 9, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will ...
On July 14, 2021 ACRX announced it had entered into two licensing agreements. The agreements make a lot of commercial sense, next to the fun fact of ACRX partnering with a syringe specialist. But there are also significant risks and uncertainties that make it hard at this stage to...
Are These Reddit Penny Stocks on Your Watchlist in 2021? Reddit penny stocks have become commonplace talking points in the stock market over the past year and a half. While the clear reason for this is heightened interest in the stock market, there are a couple of other reasons to consi...
AcelRx Pharmaceuticals (ACRX) announces that the company has entered into multiple licensing agreements for its products, including for its Dzuveo pain medicine.Has entered into an agreement with Laboratoire Aguettant for a license to commercialize Dzuveo, also known as Dsuvia, in...
AcelRx Enters into Licensing Agreement for DZUVEO® in Europe and In-licensing Agreement for Two Products in the U.S. AcelRx to receive up to approximately $55 million in combined up-front and sales-based milestone payments for DZUVEO licensing agreement AcelRx obtains t...
AcelRx Pharmaceuticals (ACRX) has reached an agreement with the FDA with regards to finalizing corrective actions it has taken or plans to take in response to the previous FDA warning letter, dated February 11, 2021, regarding certain DSUVIA promotional materials. The FDA has agreed with...
News, Short Squeeze, Breakout and More Instantly...
AcelRx Pharmaceuticals Inc. Company Name:
ACRX Stock Symbol:
NASDAQ Market:
AcelRx Pharmaceuticals Inc. Website:
AcelRx Announces Rebranding With Name Change to Talphera, Inc. PR Newswire Name change to "Talphera" reflects a new era of the Company in partnership with the medical community developing novel solutions for medically supervised settings Talphera will begin trading on ...
AcelRx Pharmaceuticals Announces Publication of Study Evaluating Anticoagulation Practices for Continuous Renal Replacement Therapy in the United States PR Newswire Use of CRRT increased during COVID and remained at these higher utilization levels Study results demonst...
AcelRx Reports Third Quarter 2023 Financial Results and Provides Corporate Update PR Newswire Niyad™ Investigational Device Exemption (IDE) approval by the FDA achieved in third quarter Company plans to begin its Niyad registrational study this quarter with topl...